BACKGROUND AND PURPOSE: Betulinic acid, a pentacyclic triterpene, is a new cytotoxic compound active on melanoma, neuroblastoma, glioblastoma and head and neck squamous cell carcinoma (HNSCC) cells. In combination with irradiation it has been shown to have an additive effect on growth inhibition in melanoma cells. In this study, the radiosensitizing effect of betulinic acid on sequential irradiation was investigated in HNSCC cell lines. MATERIAL AND METHODS: Two HNSCC cell lines, SCC9 and SCC25, were treated with increasing doses of betulinic acid and sequentially irradiated with a single boost of 4 Gy from a conventional radiation source. The cells were counted, the surviving fraction was determined, and colony-forming assays were performed. RESULTS: It could be shown that betulinic acid alone inhibits cell survival, affects cell survival additively in combination with irradiation and decreases clonogenic survival in both cell lines when applied alone. CONCLUSION: Betulinic acid could be a promising treatment agent in radioresistant head and neck cancer. A combination of betulinic acid with radiotherapy seems to be beneficial.
BACKGROUND AND PURPOSE:Betulinic acid, a pentacyclic triterpene, is a new cytotoxic compound active on melanoma, neuroblastoma, glioblastoma and head and neck squamous cell carcinoma (HNSCC) cells. In combination with irradiation it has been shown to have an additive effect on growth inhibition in melanoma cells. In this study, the radiosensitizing effect of betulinic acid on sequential irradiation was investigated in HNSCC cell lines. MATERIAL AND METHODS: Two HNSCC cell lines, SCC9 and SCC25, were treated with increasing doses of betulinic acid and sequentially irradiated with a single boost of 4 Gy from a conventional radiation source. The cells were counted, the surviving fraction was determined, and colony-forming assays were performed. RESULTS: It could be shown that betulinic acid alone inhibits cell survival, affects cell survival additively in combination with irradiation and decreases clonogenic survival in both cell lines when applied alone. CONCLUSION:Betulinic acid could be a promising treatment agent in radioresistant head and neck cancer. A combination of betulinic acid with radiotherapy seems to be beneficial.
Authors: Valentina Zuco; Rosanna Supino; Sabina C Righetti; Loredana Cleris; Edoardo Marchesi; Carlo Gambacorti-Passerini; Franca Formelli Journal: Cancer Lett Date: 2002-01-10 Impact factor: 8.679
Authors: Marlon R Veldwijk; Carsten Herskind; Leopold Sellner; Aleksandar Radujkovic; Stephanie Laufs; Stefan Fruehauf; W Jens Zeller; Frederik Wenz Journal: Strahlenther Onkol Date: 2009-08-04 Impact factor: 3.621
Authors: E Pisha; H Chai; I S Lee; T E Chagwedera; N R Farnsworth; G A Cordell; C W Beecher; H H Fong; A D Kinghorn; D M Brown Journal: Nat Med Date: 1995-10 Impact factor: 53.440
Authors: Dirk Rades; Nina D Seibold; Maximilian P Gebhard; Frank Noack; Steven E Schild; Christoph Thorns Journal: Strahlenther Onkol Date: 2011-09-19 Impact factor: 3.621
Authors: J Hübner; K Muenstedt; R Muecke; O Micke; C Stoll; U R Kleeberg; J Buentzel; G Dennert; F J Prott Journal: Strahlenther Onkol Date: 2013-07-05 Impact factor: 3.621
Authors: M Takagi; K Sakata; M Someya; Y Matsumoto; H Tauchi; M Hareyama; M Fukushima Journal: Strahlenther Onkol Date: 2012-02-11 Impact factor: 3.621
Authors: Silvia T Elias; Gabriel A Borges; Danilo A Amorim; Daniela F Rêgo; Luiz A Simeoni; Dâmaris Silveira; Yris Maria Fonseca-Bazzo; José E Paula; Christopher William Fagg; Ivelone M C Barros; Wenzel C Abreu; Décio S Pinto-Júnior; Pérola O Magalhães; Francisco A R Neves; Adriana Lofrano-Porto; Eliete N S Guerra Journal: Clin Oral Investig Date: 2014-08-07 Impact factor: 3.573
Authors: G Heiduschka; C Lill; R Seemann; M Brunner; R Schmid; R Houben; J Bigenzahn; D Thurnher Journal: Strahlenther Onkol Date: 2013-11-08 Impact factor: 3.621